BIO in tu­mult as CEO abrupt­ly ex­its; Some good PhI­II news; Da­ta is­sues still plague No­var­tis' gene ther­a­py; Hot tar­gets for M&A?; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.